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ABSTRACT
Objective: Tacrine is a potent acetylcholine esterase inhibitor (AChEI), and curcumin has been recently proven to possess AChEI, amyloid β aggregation 
inhibitory activity in addition to its diverse pharmacodynamic nature. Tacrine undergoes biological transformation by cytochrome P450 (CYP 1A2) 
to a hydroxy metabolite, which is hepatotoxic. Curcumin is known for its inhibitory nature for various metabolic enzymes along with CYP1A2. The 
present study was undertaken to evaluate the influence of curcumin on the disposition kinetics of tacrine and to assess its impact on dosage regimen.
Conclusion: Concomitant administration of curcumin with tacrine improved the parameters such as Cmax and AUC, which indicates that the curcumin 
would improve the absorption of tacrine.
Key words: Alzheimer’s disease, Curcumin, Tacrine, Pharmacokinetic studies, Reversed-phase high-performance liquid chromatography.
INTRODUCTION
Tacrine (1,2,3,4-tetrahydroacridin-9-amine; Cognex; THA) was treated 
as the first acetylcholine esterase inhibitor (AChEI) approved to use 
in the treatment of Alzheimer’s Disease (AD) by the Food and Drug 
Administration in 1993, which was most potent and clinically effective 
AChEI. It was shown significant effect as a palliative treatment for the 
AD symptoms. It possesses a very decent pharmacokinetic properties 
(e.g., penetration through blood-brain barrier and AChEI activity 
on nM scale) [1]. Shortly after its approval, it was retracted from the 
pharmaceutical market for its poor selectivity toward AChE that 
resulted in a number of serious side effects. The potential adverse effect 
of THA is liver damage, which was indicated by increased of the alanine 
aminotransferase levels. THA was prone to metabolism by cytochrome 
P450 (CYP 1A2) and resulted the different hydroxy analogs that are 
responsible for its hepatotoxicity [2].
Curcumin (diferuloylmethane) is a hydrophobic polyphenol isolated 
from the rhizomes of Curcuma longa L. (Turmeric). Mostly, turmeric is 
used as a dietary spice in most of the Asian countries. Moreover, the 
literature of traditional medicine of India and China has described 
that turmeric was used for the treatment of a range of diseases. 
Turmeric beneficial effects were attributed to the curcumin as the main 
phytochemical constituent [3]. Despite curcumin beneficial effects, its 
promotion to the clinical trials was hampered due to its poor ADME 
properties. Curcumin was revealed to possess poor absorption, limited 
tissue distribution, and rapid metabolism in the liver and intestine 
that severely curtails its bioavailability [4-7]. On the other hand, 
curcumin improves the bioavailability of other drugs by inhibiting non-
specific drug metabolizing enzymes (CYP450 isozymes) [8]. Similarly, 
curcumin suppresses drug metabolizing enzymes (CYP1A1, 1A2, 2B1, 
and 3A4) in the liver as well as decreases the inducing changes in these 
enzymes by phenobarbitone and benzo(a)pyran in the liver, lung, and 
stomach, hence increasing the pharmacokinetic parameters such as 
maximum absorption concentration (Cmax) and area under the plasma 
concentration-time curve (AUC) of the substrate compound [9-11]. 
Curcumin has also shown hepatoprotective [12], nephroprotective [13], 
AChE inhibitory [14], and amyloid β protein aggregation inhibitory 
activities in vivo [15].
With this background, the present study was initiated to evaluate the 
influence of curcumin on disposition kinetics of tacrine and to assess its 
impact on dosage regimen. It was hypothesized that the simultaneous 
administration of curcumin and tacrine can minimize the toxicity along 
with increased absorption of tacrine and curcumin into the biological 
system during the treatment of Alzheimer’s patients. Hence, an attempt 
was made to develop a simple, precise, accurate, and cost-effective 
reversed-phase high-performance liquid chromatography (RP-HPLC) 
method for simultaneous determination of curcumin and tacrine and 




Reference standards of curcumin, tacrine, and tenofovir (IS) with 
purity of >97% were purchased from the Sigma-Aldrich Laboratories 
(Bengaluru, India). HPLC grade acetonitrile, water, glacial acetic acid, 
and AR grade of Sodium citrate and diethyl ether were purchased from 
SD Fine Chemicals (Mumbai, India).
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i9.26831
Research Article
Results: Hence, an attempt was made to develop a simple, precise, accurate, and cost-effective reversed-phase high-performance liquid 
chromatography method for simultaneous determination of curcumin and tacrine and also to estimate the effect of curcumin on absorption of 
tacrine, in rat plasma.
Methods: It was hypothesized that the simultaneous administration of curcumin and tacrine can minimize the toxicity along with increased absorption 
of tacrine and curcumin into the biological system during the treatment of Alzheimer’s patients.
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Instruments
The following instruments were used: Shimadzu ultraviolet (UV-1800) 
double-beam UV-visible spectrophotometer, Shimadzu SPD 10A HPLC 
system, Remi RM 12C Centrifuge, Blue Star Refrigerator, sonicator 
(Hwashin Technology, Korea), Remi CM101 cyclomixer, micropipettes 
(10–100 µL and 100–1000 µL), Eppendorf tubes, and heparinized 
capillaries (Tarsons Products Pvt. Ltd., Kolkata, India).
Experimental animals
Healthy male albino rats (250–300 g) were used in this study in 
accordance with institutional guidelines and approval of local ethics 
authorities (1047/ac/07/CPCSEA, Dated 24-04-2007). These were 
purchased from Teena BioLabs, Hyderabad, Telangana. The animals 
were maintained on a 12 h light–dark cycle (light on from 8:00 to 
20:00 h) at an ambient temperature of 25±2°C and 50±15% relative 
humidity. Rats were fed with a commercial pellet diet (Hindustan 
lever Pvt. Ltd., Mumbai, India) and water ad libitum. They were fasted 
overnight before the experiment, and during the experiment, the food 
is withdrawn but not the water.
HPLC analysis
The HPLC system consisted of a Shimadzu class 10A series with a 50 µL 
sample loop coupled to SPD 10AVP UV-visible detector set to 241 nm 
and a computer system for data acquisition (Class LC-10AT series 
version 5.03, Shimadzu) was used. The separation was achieved using 
a reversed phase C-18 column (4.6 mm × 250 mm, particle size 5 µm). 
Mobile phase consisting of acetonitrile: Water containing 0.1% glacial 
acetic acid: (70:30% v/v) was employed at a flow rate of 1.0 mL/min.
Preparation of standard solutions
Primary stock solutions of tenofovir (Internal standard) were prepared 
at a concentration of 1 mg/mL using acetonitrile as a solvent and stored 
at −20°C.
Standard graph procedure
Primary stock solution of tenofovir was diluted with acetonitrile to 
obtain the working solution of 100 µg/mL concentration. To 100 µL 
of plasma samples, 20 µL of internal standard from 100 µg/mL of 
working solution was added to obtain 20 µg/mL final concentration, 
and 20 µL of tacrine was added from each concentration to obtain final 
concentrations of 200, 300, 400, 1500, and 4000 ng/mL of tacrine. To 
100 µL of plasma samples, 20 µL of internal standard from 100 µg/mL 
of working solution was added to obtain 20 µg/mL final concentration, 
and 20 µL of curcumin was added from each concentration to obtain 
final concentrations of 1000, 2000, 3000, 4000, and 5000 ng/mL of 
curcumin. The resultant solution was mixed for 2 min on cyclomixer 
at room temperature, and 400 µL of acetonitrile was added and 
centrifuged at 4000 rpm for 10 min. The supernatant was separated 
which is called Supernatant I and 400 µL of acetonitrile was added 
to residue and the resultant solution was mixed again for 2 min on 
cyclomixer at room temperature and centrifuged at 4000 rpm for 
20 min, and then Supernatant II was added to the Supernatant I. The 
pooled Supernatants I and II were collected and kept for evaporation 
to dryness on water bath, the residue was dissolved in 200 µL of 
acetonitrile, and after filtration through 0.2 µm syringe filter, 20 µL of 
the solution was spiked for the HPLC analysis [16].
The peak area of the drugs and internal standard was determined, and 
the peak area ratio was calculated using the formula
Peak area ratio = peak area of drug/peak area of internal standard
Graph is plotted by taking peak area ratio on Y-axis and concentration 
on X-axis. The standard graph was considered to be significant when 
the r2 value is ≥0.99.
Extraction procedures (LLE)
100 µL of the collected plasma samples were taken, to it 20 µL of 1 mg/mL 
tenofovir and 400 µL of acetonitrile was added, the resulting solution 
was vortexed for 5 min on cyclomixer and centrifuged at 2000 rpm 
for 10 min, and the supernatant layer was separated. The residue was 
added with another 400 µL of acetonitrile and mixed again for 5 min on 
cyclomixer and centrifuged at 2000 rpm for 10 min. Then, supernatant 
was separated and added to previously separated supernatant layer. 
The collected supernatant liquid was evaporated to dryness on water 
bath, the obtained residue was dissolved in 100 µL of mobile phase and 
filtered through 0.2 µm syringe filter, and 20 µL of the filtered solution 
was used for the HPLC analysis [17-21].
HPLC method validation
The developed analytical method was validated by the following 
ICH guidelines for selectivity, precision, accuracy, linearity, limit of 
detection (LOD), lower limit of quantitation (LOQ), robustness, and 
ruggedness [22,23].
Pharmacokinetic study of tacrine and curcumin
Grouping of animals
Albino rats (4) were grouped as follows: Group I: Control (5% gum 
acacia 10 mL/kg per oral), Group II: Curcumin (80 mg/kg for single 
day), Group III: Tacrine (4 mg/kg for single day), and Group IV: Tacrine 
and curcumin (tacrine 4 mg/kg and curcumin 80 mg/kg for single day).
Albino rats were administered with drugs as mentioned above. Blood 
samples (0.3 mL) were collected through retro-orbital plexus under mild 
ether anesthesia at a time period of 0, 1, 2, 3, 4, 6, and 12 h following drug 
administration using sodium citrate (3.8%) as an anticoagulant. Blood 
samples were immediately centrifuged at 2000 rpm for 10 min, and the 
plasma was separated and stored at −20°C until analysis. At the time of 
analysis, the stored plasma was used for extraction as described above.
After determining the concentration of tacrine and curcumin in extracted 
plasma, the graph was plotted by taking average concentration values 
of tacrine and curcumin in plasma samples on Y-axis and corresponding 
time in hours on X-axis. Various pharmacokinetic parameters such as 
Cmax, Tmax, AUC, MRT, t1/2 and KE, Vd, and Cl were calculated by applying 
non-compartment model using Kinetica 5.0 software [24,25].
RESULTS AND DISCUSSION
Method development for evaluation of tacrine and curcumin
The absorbance of tacrine and curcumin was scanned entire UV 
range (i.e., 200–400 nm) using a Shimadzu double-beam UV-visible 
spectrophotometer (UV 1800), and the maximum absorbance (λmax) 
was found at of 241 nm wavelength. Therefore, the wavelength of 
241 nm was chosen for the present study. Acetonitrile: Water containing 
0.1% glacial acetic acid: 70:30% v/v was used as the mobile phase. 
The mobile phase was attained the optimal separation of tacrine and 
curcumin. The internal standard, i.e., tenofovir was not interfered with 
the other components in plasma samples.
HPLC method validation
Specificity and Sensitivity
Chromatograms of tacrine, curcumin, and tenofovir (internal standard) 
were obtained from rat plasma extracts of the drugs were represented 
in Fig. 1. The endogenous compound peaks were not interfered with 
the detection of tacrine, curcumin, and I.S (tenofovir) at their respective 
retention times (tacrine Rt = 4.67 min, curcumin Rt = 9.19 min, and I.S 
(tenofovir) Rt = 7.01 min) in blank. LOD was found to be 0.193 and 0.217 
and LOQ was found to be 0.586 and 0.660 for tacrine and curcumin, 
respectively, and the corresponding results are presented in Table 1.




LOD: Limit of detection, LOQ: Limit of quantitation
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Linearity of calibration curve
The calibration curves of tacrine and curcumin were found to be linear 
over the concentration range of 200–4000 and 1000–5000 ng/mL, 
respectively. Correlation coefficient of tacrine and curcumin was 0.999 
and 0.998, respectively. The results are shown in Figs. 2 and 3 and 
Table 2.
Precision and accuracy
Table 3 shows the data of intra- and inter-day precision and accuracy. 
Accuracy of 200, 400, and 1500 ng/mL was found to be 99.1, 96.3, and 
99.1 for tacrine, and accuracy of 1000, 2000, and 3000 ng/mL was 
found to be 99.1, 98.43, and 98.74 for curcumin. The intra- and inter-
day precisions (% deviation) were falling within < ±2% for the LOQ. 
The intra- and inter-day assay precision (CV) ranged from 1.56 to 0.21 
and 1.8 to 0.85% for tacrine and curcumin, respectively. These results 
indicated that the present assay has very good accuracy and precision. 
The results are shown in Tables 3-5.
Robustness
By changing the wavelength (246 and 236 nm) and flow rate (0.9 and 
1.1 mL/min) of the mobile phase, the robustness was studied. The 
results are shown in Tables 6 and 7. The results were satisfactory.
Ruggedness
The operating conditions were changed during the experiment with a 
standard solution of the drug substance. The conditions were changed 
and examined, including different operator, different instrument, 
different laboratory, changing source of reagent and solvent, and 
changing a new column.
System suitability parameters for curcumin and tacrine
These tests were performed to check the suitability of the 
chromatographic system for the intended analysis. The tests were 
basically related to the equipment performance, analytical operations, 
and sample constituents. And the evaluation results were shown in 
Table 8.
Factors that may affect chromatographic behavior include the 
following: Mobile phase related, including the composition of solvents, 
ionic strength, temperature, and apparent pH; stationary phase 
related, including type of chromatographic support (particle-based or 
monolithic) particle or macropore size, porosity, and specific surface 
area; and operational related, including flow rate, column dimensions, 
column temperature, and pressure.
Pharmacokinetic data
The concentration of tacrine and curcumin in extracted plasma was 
determined, and the graph was plotted by taking average concentration 
(ng/mL) values of drug in plasma samples on Y-axis and corresponding 
time in hours on X-axis. The pharmacokinetic data of tacrine and 
curcumin are depicted in Tables 9-13. The influence of concomitant 
administration of curcumin on tacrine disposition was demonstrated 
by the serum concentration profiles as shown in Figs. 4-10, and the 
pharmacokinetic parameters are shown in Table 14.
Both curcumin and tacrine reached maximum concentration after 3 h 
of oral administration. The mean concentration of tacrine and curcumin 
was found to be 56.65±1.61 and 49.91±5.87 ng/mL. Surprisingly, the 
mean Cmax of tacrine was improved to 73.42±2.16 ng/mL, when these 
two were administered concomitantly. The AUC values obtained in 
the oral administration of tacrine and curcumin were 742.78 and 
672.35 ng.h/mL, respectively, whereas the t1/2 was 1.09 and 0.98 h−1. 
Fig. 1: Chromatogram of tacrine and curcumin with IS (tenofovir)
Fig. 2: Calibration curve for tacrine
Fig. 3: Calibration curve for curcumin
Table 2: Linearity data for curcumin and tacrine
S. No Curcumin Tacrine
Concentration (ng/mL) Peak area Concentration (ng/mL) Peak area
1 1000 26734.8 200 27699.75
2 2000 45779.94 300 31106.35
3 3000 62312.59 400 34900.55
4 4000 83914.91 1500 38219
5 5000 102384.2 4000 41363.2
Statistical analysis Slope: 18943
Y-intercept: 7395.1
Correlation coefficient (R2): 0.998
Slope: 3444
Y-intercept: 24326
correlation coefficient (R2): 0.999
340
Asian J Pharm Clin Res, Vol 11, Issue 9, 2018, 337-343
 Alavala et al. 
Table 3: Precision data
Intraday
Concentration (ng/mL) Mean SD %RSD
200 15164.7 125.21 0.82
400 39035.62 82.18 0.21
1500 57539.48 901.74 1.56
Interday
Concentration (ng/mL) Mean SD %RSD
200 15136.21 142.5 0.94
400 38919.23 338.51 0.85
1500 58051.36 1098.5 1.8
Table 4: Accuracy study data for tacrine
Accuracy




Table 5: Accuracy study data for curcumin
Accuracy




Table 6: Robustness (flow rate)
Flow rate Drug Theoretical concentration ng/mL Mean (Peak area) Rt value %RSD
0.9 mL/min Tacrine 200 12593.652 4.67 0.95
400 20165.781 4.68 1.02
Curcumin 1000 19568.652 9.18 1.16
2000 149100.422 9.18 1.09
1.1 mL/min Tacrine 200 12581.622 4.71 1.04
400 20162.521 4.70 1.5
Curcumin 1000 19668.652 9.24 1.38
2000 149909.422 9.24 1.18
Table 7: Robustness (wavelength)
Wavelength Drug Theoretical concentration µg/mL Mean (peak area) Rt value %RSD
246 nm Tacrine 200 12581.622 4.68 1.25
400 20162.521 4.67 0.97
Curcumin 1000 19668.652 9.36 1.29
2000 149909.422 9.39 1.41
236 nm Tacrine 200 12593.652 4.68 1.32
400 20165.781 4.68 1.26
Curcumin 1000 19568.652 9.29 1.09
2000 149100.422 9.22 0.73
Table 8: System suitability parameters
Replicate injections Curcumin Tacrine
R Peak area N T R Peak area N T
1 4.67 5684004 3894.2 2.068 9.18 1344089 132771 1.793
2 4.66 5679100 3771.3 2.041 9.08 1344110 1327101 1.802
3 4.67 5714319 3821.4 2.059 9.06 1343969 133660 1.811
4 4.65 5809930 3915.0 2.04 9.21 1344210 134917 1.786
5 4.64 5871163 3891.3 2.01 9.16 1344036 1352121 1.719
6 4.67 5670119 3796.2 1.97 9.19 1343987 1357432 1.788
Statistical analysis Mean 4.66 5738049 3848.21 2.0313 9.14 1344067 1341688 1.7831
SD 0.0116 83.05 59.627 0.036 0.0453 8.914 130.13 0.032
%RSD 0.19 1.44 1.54 1.77 0.45 0.006 0.969 1.794
Fig. 4: Time versus concentration profile of tacrine and curcumin single day
Fig. 5: AUC of tacrine and curcumin after single day oral 
administration (*p<0.05; **p<0.01; ***p<0.001) when compared 
with the tacrine and curcumin alone by using one-way ANOVA
followed by Dunnett’s test
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When these two were given concomitantly, the AUC of tacrine was found 
to be 937.56 ng.h/mL and the t1/2 was 1.05 h−1. MRT was not altered 
by curcumin (tacrine - 1.68 h and tacrine and curcumin - 1.67 h). The 
clearance of tacrine alone was 0.09 L/h and when it was given along 
with curcumin was 0.10 L/h, whereas the volume of distribution was 
1.60 and 1.50 L for tacrine alone and in combination, respectively.
Table 9: Concentration and time profile of tacrine after oral administration on single day
Time (h) Animal 1 Animal 2 Animal 3 Animal 4 Mean SD
0 0 0 0 0 0 0
1 6.943 7.258 8.521 8.836 7.89 0.232
2 19.078 19.945 23.414 24.281 21.68 0.638
3 49.85 52.11 61.182 63.448 56.65 1.611
4 29.881 24.545 28.814 23.478 26.68 0.785
6 7.840 9.622 9.979 8.197 8.91 0.262
12 5.129 4.213 4.946 4.030 4.58 0.134
Table 10: Concentration and time profile of curcumin after oral administration on single day
Time (h) Animal 1 Animal 2 Animal 3 Animal 4 Mean SD
0 0 0 0 0 0 0
1 11.40 13.88 10.912 13.284 12.4 1.43
2 19.71 24.19 25.08 20.60 22.4 2.63
3 45.91 55.89 43.92 53.90 49.91 5.87
4 21.85 17.94 21.070 17.168 19.51 2.30
6 9.18 7.54 8.85 7.21 8.2 0.96
12 3.66 3.83 4.50 4.67 4.17 0.49
Table 11: Concentration and time profile of tacrine and curcumin after oral administration on single day
Time (h) Animal 1 Animal 2 Animal 3 Animal 4 Mean SD
0 0 0 0 0 0 0
1 14.517 13.886 17.673 17.042 15.78 0.564
2 22.595 27.507 21.612 26.524 24.56 0.722
3 67.546 64.609 79.293 82.230 73.42 2.161
4 36.396 46.323 44.668 38.051 41.36 1.217
6 19.084 15.676 14.995 18.403 17.04 0.501
12 3.836 4.011 4.708 4.883 4.36 0.128
Table 12: Pharmacokinetic data of tacrine after single day administration
Animal Cmax (ng/mL) Tmax (h) AUC (ng.h/mL) t ½(h−1) MRT (h) Cl (L/h) Vd (L)
1 49.85 3 626.537 0.854 1.347 0.091 1.33
2 52.11 3 711.682 1.041 1.557 0.085 1.472
3 61.18 3 875.511 1.431 2.255 0.098 1.956
4 56.65 3 757.429 1.044 1.598 0.112 1.644
Mean 56.65 3 742.7898 1.0925 1.68925 0.0965 1.6005
SD 1.61 0 103.7812 0.242535 0.392863 0.011619 0.26954
Table 13: Pharmacokinetic data of curcumin after single day administration
Animal Cmax (ng/mL) Tmax (h) AUC (ng.h/mL) t ½ (h−1) MRT (h) Cl (L/h) Vd (L)
1 45.91 3 576.960 0.787 1.241 0.083 1.216
2 55.89 3 763.30 1.116 1.669 0.091 1.576
3 43.92 3 628.492 1.027 1.618 0.070 1.397
4 53.90 3 720.661 0.993 1.520 0.106 1.555
Mean 49.91 3 672.3533 0.98075 1.512 0.0875 1.436
SD 5.87 0 84.90903 0.139189 0.190954 0.015067 0.167015
Table 14: Pharmacokinetic data of tacrine and curcumin after single day administration
Animal Cmax (ng/mL) Tmax (h) AUC (ng.h/mL) t½ (h−1) MRT (h) Cl (L/h) Vd (L)
1 67.546 3 852.154 0.881 1.435 0.0921 1.189
2 64.609 3 858.53 0.979 1.579 0.106 1.403
3 79.293 3 1009.255 1.270 1.878 0.104 1.668
4 82.230 3 1030.32 1.085 1.793 0.110 1.778
Mean 73.42 3 937.5648 1.05375 1.67125 0.103025 1.5095
SD 2.161 0 95.36686 0.166504 0.201571 0.007699 0.265378
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Statistical analysis indicated that the differences in Cmax and AUC 
between two treatments were significant. Curcumin increased both 
the parameters that indicate that the curcumin would improve the 
absorption of tacrine. Other pharmacokinetic parameters were not 
significantly affected by coadministration of curcumin. Although CYP 
1A2 is the main isozymes thought to catalyze tacrine metabolism and 
curcumin demonstrated potent inhibition on rat liver CYP 1A1/1A2, our 
present study indicated that the effects of concomitant administration 
of curcumin on tacrine systemic clearance were generally negligible. 
This could be due to the poor absorption of curcumin from the gut.
CONCLUSION
The present investigation was designed based on the hypothesis of 
curcumin and tacrine simultaneous administration can minimize the 
toxicity of tacrine and improves its bioavailabity along with its biological 
activities may improve the therapeutic approach for the treatment of AD. 
Hence, an attempt was made to study the pharmacokinetic interaction 
of curcumin and tacrine when they administered simultaneously with 
the help of cost-effective RP-HPLC method. From the present study, we 
can conclude that there is a significant effect of curcumin on tacrine 
pharmacokinetic parameters which is a desirable effect. However, an 
extensive research is needed to prove the effect of curcumin on chronic 
treatment.
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Fig. 6: Cmax of tacrine and curcumin after single day oral 
administration.  (*p<0.05; **p<0.01; ***p<0.001) when compared 
with the tacrine and curcumin alone using one-way ANOVA
followed by Dunnett’s test
Fig. 8: MRT of tacrine and curcumin after single day oral 
administration
Fig. 9: Clearance of tacrine and curcumin after single day oral 
administration. (*p<0.05; **p<0.01; ***p<0.001) when compared 
with the tacrine and curcumin alone using one-way
ANOVA followed by Dunnett’s test
Fig. 7: Half-life of tacrine and curcumin after single day oral 
administration Fig. 10: Vd of tacrine and curcumin after single day oral 
administration. 
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Graphical Abstract
A simple, precise, accurate, and cost-effective reversed-phase HPLC 
(RP-HPLC) method was developed for simultaneous determination 
of curcumin and tacrine and also to estimate the pharmacokinetic 
interactions of curcumin on tacrine.
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